ストックスクリーナーアプリを入手
3.73
1.36%
0.05
プレマーケット:
3.64
-0.09
-2.41%
Aquestive Therapeutics Inc (AQST) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AQST|Aquestive Therapeutics Inc|Price:3.680|Chg%:-0.090 - TradingKey
Aquestive Therapeutics Inc (AQST) Balance Sheet - TradingKey
2026-07-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Inc (AQST) Cash Flow - TradingKey
Aquestive Therapeutics Inc (AQST) Income Statement - TradingKey
Aquestive Therapeutics Inc (AQST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - ACCESS Newswire
ETFs Investing in Aquestive Therapeutics, Inc. Stocks - TradingView
Aquestive Therapeutics Inc (AQST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Price to book forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Enterprise value to EBITDA forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Price to sales forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Enterprise value to revenue forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Form 4 Aquestive Therapeutics Inc For: 17 July By Investing.com - Investing.com South Africa
Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE - GuruFocus
Aquestive Therapeutics president and CEO Daniel Barber sells $100,191 in stock - Investing.com Canada
Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04 - Stock Titan
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $100,201.97 - Bitget
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review
2026-07-16 | Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Enterprise value to EBIT forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review
Form 144 Aquestive Therapeutics For: 15 July By Investing.com - Investing.com South Africa
Price to earnings forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Inc (AQST) Institutional Confidence - TradingKey
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics (AQST) Faces Selling Pressure, Tests Support Near $3.91Cash Flow Strong Stocks - dars.gov.et
2026-07-12 | Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
Aquestive Therapeutics, Inc. SEC Filing (Jul 9, 2026) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - Investing News Network
Aquestive Therapeutics to present at Leerink Pa... - Pluang
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
2026-07-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
AQSTAquestive Therapeutics Inc Short Interest - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
SEC Form S-3 filed by Aquestive Therapeutics Inc. - Quantisnow
Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com - Investing.com India
Aquestive Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST) - TradingView
symbol__ Stock Quote Price and Forecast - CNN
AQST Forecast — Price Target — Prediction for 2027 - TradingView
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9 - Moomoo
0.30%
2.01%
大文字化:
|
ボリューム (24 時間):